TABLE 3.
Independent and combined accuracy metrics of GEP and SLNB in patients with GEP results and SLNB status
| METRICS | GEP % (95% CI) | SLNB % (95% CI) | GEP & SLNB % (95% CI) |
|---|---|---|---|
| RFS | n=1,479 | n=867 | n=867 |
| Sensitivity | 76 (71–80) | 57 (51–63) | 88 (84–92) |
| Specificity | 76 (73–78) | 74 (70–77) | 52 (48–56) |
| DMFS | n=1,223 | n=867 | n=867 |
| Sensitivity | 76 (70–82) | 61 (55–68) | 90 (85–94) |
| Specificity | 69 (66–72) | 72 (68–75) | 48 (44–52) |
CI: Confidence interval; DMFS: distant metastasis-free survival; GEP: gene expression profile; RFS: recurrence-free survival; SLNB: sentinel lymph node biopsy
Adapted from Greenhaw BN, Covington KR, Kurley SJ, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol.202083(3):745-753.